Johnson & Johnson $JNJ is Bar Harbor Wealth Management’s 6th Largest Position

Bar Harbor Wealth Management lessened its position in shares of Johnson & Johnson (NYSE:JNJ) by 3.7% in the 1st quarter, HoldingsChannel reports. The fund owned 198,273 shares of the company’s stock after selling 7,598 shares during the period. Johnson & Johnson accounts for about 2.8% of Bar Harbor Wealth Management’s portfolio, making the stock its 6th biggest holding. Bar Harbor Wealth Management’s holdings in Johnson & Johnson were worth $48,466,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Auto Owners Insurance Co increased its stake in Johnson & Johnson by 22,225.6% in the fourth quarter. Auto Owners Insurance Co now owns 69,419,308 shares of the company’s stock valued at $1,436,633,000 after purchasing an additional 69,108,368 shares during the last quarter. Norges Bank purchased a new stake in shares of Johnson & Johnson during the 4th quarter worth approximately $6,924,523,000. Capital World Investors acquired a new position in shares of Johnson & Johnson in the 4th quarter valued at $2,005,942,000. Vanguard Group Inc. grew its position in shares of Johnson & Johnson by 1.6% in the 4th quarter. Vanguard Group Inc. now owns 240,349,660 shares of the company’s stock valued at $49,740,362,000 after buying an additional 3,731,074 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD grew its position in shares of Johnson & Johnson by 41.7% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 12,423,886 shares of the company’s stock valued at $2,571,124,000 after buying an additional 3,655,754 shares during the last quarter. 69.55% of the stock is owned by hedge funds and other institutional investors.

Key Stories Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Johnson & Johnson was highlighted as a top dividend-safe name, with multiple articles arguing that its reliable cash flows and long dividend track record make it an attractive holding for income-focused investors. One Stock to Own For Ultimate Dividend Safety
• Positive Sentiment: The company advanced its cardiac ablation technology in Europe with the availability of its Dual Energy THERMOCOOL SMARTTOUCH SF Platform, a reminder that JNJ continues to expand its medtech portfolio and commercial reach. Johnson & Johnson Advances Cardiac Ablation Technology in Europe with Availability of Dual Energy THERMOCOOL SMARTTOUCH SF Platform
• Neutral Sentiment: Analysts are looking for a single-digit earnings increase when Johnson & Johnson reports second-quarter results in July, which suggests stable but not explosive near-term growth expectations. Johnson & Johnson Earnings Preview: What to Expect
• Neutral Sentiment: Recent market commentary also noted JNJ rising while broader markets dipped, indicating investor preference for defensive stocks rather than a company-specific catalyst. Johnson & Johnson (JNJ) Rises As Market Takes a Dip: Key Facts

Insiders Place Their Bets

In other Johnson & Johnson news, EVP Kathryn E. Wengel sold 10,000 shares of Johnson & Johnson stock in a transaction that occurred on Thursday, June 11th. The stock was sold at an average price of $241.15, for a total value of $2,411,500.00. Following the transaction, the executive vice president directly owned 114,288 shares in the company, valued at approximately $27,560,551.20. This trade represents a 8.05% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 0.16% of the company’s stock.

Johnson & Johnson Trading Up 1.6%

Shares of Johnson & Johnson stock opened at $244.93 on Friday. The company has a debt-to-equity ratio of 0.46, a quick ratio of 0.77 and a current ratio of 1.03. The company has a market capitalization of $589.61 billion, a P/E ratio of 28.32, a PEG ratio of 2.36 and a beta of 0.26. Johnson & Johnson has a 1 year low of $151.01 and a 1 year high of $251.71. The company’s fifty day moving average is $230.60 and its two-hundred day moving average is $229.25.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Tuesday, April 14th. The company reported $2.70 EPS for the quarter, beating analysts’ consensus estimates of $2.68 by $0.02. Johnson & Johnson had a net margin of 21.83% and a return on equity of 32.60%. The business had revenue of $24.06 billion during the quarter, compared to analysts’ expectations of $23.60 billion. During the same period in the prior year, the company earned $2.77 earnings per share. The business’s revenue was up 9.9% compared to the same quarter last year. Johnson & Johnson has set its FY 2026 guidance at 11.450-11.650 EPS. Analysts forecast that Johnson & Johnson will post 11.57 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, June 9th. Shareholders of record on Tuesday, May 26th were paid a dividend of $1.34 per share. The ex-dividend date of this dividend was Tuesday, May 26th. This represents a $5.36 annualized dividend and a yield of 2.2%. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.30. Johnson & Johnson’s dividend payout ratio (DPR) is currently 61.97%.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on JNJ shares. Argus boosted their price target on shares of Johnson & Johnson from $240.00 to $275.00 and gave the company a “buy” rating in a research report on Thursday, April 16th. Guggenheim raised their price objective on Johnson & Johnson from $244.00 to $266.00 and gave the stock a “buy” rating in a report on Monday, April 20th. Stifel Nicolaus boosted their target price on Johnson & Johnson from $220.00 to $250.00 and gave the company a “hold” rating in a report on Wednesday, April 15th. Citigroup upped their target price on Johnson & Johnson from $274.00 to $285.00 and gave the company a “buy” rating in a research report on Tuesday, April 7th. Finally, Bank of America raised their price target on Johnson & Johnson from $253.00 to $254.00 and gave the stock a “neutral” rating in a research note on Wednesday, April 15th. Twenty research analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the company’s stock. According to MarketBeat, Johnson & Johnson presently has a consensus rating of “Moderate Buy” and an average price target of $253.04.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.